TUBA4A downregulation as observed in ALS

Disease-associated variants of

Informations de copyright

Copyright © 2024 Van Schoor, Strubbe, Braems, Weishaupt, Ludolph, Van Damme, Thal, Bercier and Van Den Bosch.

Déclaration de conflit d'intérêts

ACL serves on the Advisory Board of Roche Pharma (Basel, Switserland) and Biogen (Cambridge, MA, USA), and on the data and safety monitoring board of Zeneus pharma (Bray, UK). ACL received consulting fees from AB Science (Paris, France), Desitin (Buckinghamshire, UK), Novartis (Basel, Switserland) and Teva (Jerusalem, Israel). PVD participated in advisory board meetings of Biogen (Cambridge, MA, USA), Cytokinetics (San Francisco, CA, USA), Ferrer (Barcelona, Spain), UCB (Brussels, Belgium), Argenx (Ghent, Belgium), Muna Therapeutics (Copenhagen, Denmark), Alector (San Francisco, CA, USA), Augustine Therapeutics (Leuven, Belgium), Alexion Therapeutics (Boston, MA, USA) and QurAlis (Cambridge, MA, USA). DRT received speaker honorary or travel reimbursement from Biogen (USA), UCB (Brussels, Belgium), and collaborated with Novartis Pharma AG (Basel, Switzerland), Probiodrug [Halle (Saale), Germany, GE Healthcare Amersham, UK], and Janssen Pharmaceutical Companies (Beerse, Belgium). LVDB is scientific founder and head of the Scientific Advisory Board of Augustine Therapeutics (Leuven, Belgium). The funders had no role in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.